Home >> Signaling Pathways >> Tyrosine Kinase >> ALK

ALK

ALK (anaplastic lymphoma kinase) is a member of insulin receptor protein-tyrosine superfamily, functioning in embryonic development and involved in cell survival and cell fate.

Products for  ALK

  1. Cat.No. Product Name Information
  2. GC14729 (R)-Crizotinib

    PF 2341066

    A c-MET and ALK receptor tyrosine kinase inhibitor (R)-Crizotinib  Chemical Structure
  3. GC13136 (S)-Crizotinib Potent MTH1 inhibitor (S)-Crizotinib  Chemical Structure
  4. GC33319 2-Keto Crizotinib (PF-06260182) 2-Keto Crizotinib (PF-06260182) (PF-06260182) is an active lactam metabolite of crizotinib. 2-Keto Crizotinib (PF-06260182)  Chemical Structure
  5. GC35280 Alectinib Hydrochloride Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration. Alectinib Hydrochloride  Chemical Structure
  6. GC35287 ALK inhibitor 1 ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=31 nM) and focal adhesion kinase (FAK; IC50=2 nM). ALK inhibitor 1  Chemical Structure
  7. GC17376 ALK inhibitor 2 An inhibitor of TSSK2 ALK inhibitor 2  Chemical Structure
  8. GC63387 ALK kinase inhibitor-1 ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202. ALK kinase inhibitor-1  Chemical Structure
  9. GC73642 ALK-IN-26 ALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26  Chemical Structure
  10. GC73883 ALK-IN-28 ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK). ALK-IN-28  Chemical Structure
  11. GC35289 ALK-IN-5 ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK), with an IC50 of 2.9 nM. ALK-IN-5  Chemical Structure
  12. GC35290 ALK-IN-6 ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC50 values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively. ALK-IN-6  Chemical Structure
  13. GC17283 AP26113

    Brigatinib

    AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113  Chemical Structure
  14. GC14446 ASP3026

    ASP 3026;ASP-3026

    An ALK inhibitor ASP3026  Chemical Structure
  15. GC14189 AZD-3463

    ALK/IGF1R inhibitor

    ALK/IGF1R inhibitor AZD-3463  Chemical Structure
  16. GC19063 Belizatinib

    TSR-011

    Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase. Belizatinib  Chemical Structure
  17. GC19508 BLU-782

    Activin Receptor-like Kinase 2 Inhibitor 1, ALK2-IN-1, Fidrisertib

    BLU-782 is an oral precision therapy specifically designed to selectively target mutant ALK2. BLU-782  Chemical Structure
  18. GC19084 Brigatinib

    Brigatinib

    A highly potent and selective ALK inhibitor Brigatinib  Chemical Structure
  19. GC15145 CEP-28122 anaplastic lymphoma kinase (ALK) inhibitor CEP-28122  Chemical Structure
  20. GC35652 CEP-28122 mesylate salt CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt  Chemical Structure
  21. GC15273 CEP-37440 FAK/ALK inhibitor,potent and selective CEP-37440  Chemical Structure
  22. GC45789 Ceritinib-d7

    LDK 378-d7

    An internal standard for the quantification of ceritinib Ceritinib-d7  Chemical Structure
  23. GC16025 CH5424802

    Alectinib, RO5424802

    CH5424802 (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. CH5424802 demonstrates effective central nervous system (CNS) penetration. CH5424802  Chemical Structure
  24. GC12616 Crizotinib hydrochloride

    inhibitor of the c-Met kinase and the NPM-ALK

    Crizotinib hydrochloride  Chemical Structure
  25. GC73579 DDO-2728 DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM. DDO-2728  Chemical Structure
  26. GC14298 DMH-1

    BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482

    Selective BMP ALK2 receptor DMH-1  Chemical Structure
  27. GC33190 Ensartinib (X-396)

    X-396

    Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib (X-396)  Chemical Structure
  28. GC32864 Ensartinib hydrochloride (X-396 hydrochloride)

    X-396 dihydrochloride

    Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib hydrochloride (X-396 hydrochloride)  Chemical Structure
  29. GC14476 Entrectinib

    NMS-E628, RXDX-101

    Orally active inhibitor of ALK kinase Entrectinib  Chemical Structure
  30. GC72974 Entrectinib-d8

    NMS-E628-d8; RXDX-101-d8

    Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib. Entrectinib-d8  Chemical Structure
  31. GC65380 Envonalkib Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer. Envonalkib  Chemical Structure
  32. GC36021 F-1 F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1  Chemical Structure
  33. GC73406 Ficonalkib Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the tyrosine kinase receptor. Ficonalkib  Chemical Structure
  34. GC12273 GSK1838705A IGF-IR/IR/ALK inhibitor, ATP-competitive GSK1838705A  Chemical Structure
  35. GC36222 HG-14-10-04 An ALK inhibitor HG-14-10-04  Chemical Structure
  36. GC33062 JH-VIII-157-02 JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. JH-VIII-157-02  Chemical Structure
  37. GC13902 KRCA 0008 Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor KRCA 0008  Chemical Structure
  38. GC14552 LDK378

    LDK 378;LDK-378;Ceritinib

    LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. LDK378  Chemical Structure
  39. GC17452 LDK378 dihydrochloride LDK378 dihydrochloride  Chemical Structure
  40. GC50327 LDN 193189 dihydrochloride

    DM-3189

    Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs LDN 193189 dihydrochloride  Chemical Structure
  41. GC16580 LDN-193189

    LDN 193189;LDN193189

    ALK inhibitor,potent and selective LDN-193189  Chemical Structure
  42. GC17035 LDN-212854 BMP receptor inhibitor,potent and selective LDN-212854  Chemical Structure
  43. GC13225 LDN-214117 potent and selective ALK2 inhibitor LDN-214117  Chemical Structure
  44. GC14931 LDN193189 Hydrochloride

    LDN 193189 hydrochloride; LDN-193189 hydrochloride

    LDN193189 Hydrochloride is a selective inhibitor of the transcriptionally active morphogenetic protein (BMP) type I receptor, a family of BMP receptors that includes activin receptor-like kinases (ALK1, ALK2, ALK3, and ALK6). LDN193189 Hydrochloride inhibits ALK2 and ALK3 with IC50 values of 5nM and 30nM, respectively. LDN193189 Hydrochloride  Chemical Structure
  45. GC69422 M4K2234

    M4K2234 (compound 26b) is an inhibitor of ALK2. M4K2234 inhibits ALK2 and ALK5 with IC50 values of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for the protein kinases ALK1 and ALK2. M4K2234 can be used in cancer research.

    M4K2234  Chemical Structure
  46. GC17582 ML347

    LDN193719

    BMP receptor inhibitor,potent and selective ML347  Chemical Structure
  47. GC65243 MS4077 MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK. MS4077  Chemical Structure
  48. GC64966 MS4078 MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK. MS4078  Chemical Structure
  49. GC73649 Neladalkib TFA

    NVL-655 TFA

    Neladalkib TFA is the TFA form of Neladalkib. Neladalkib TFA  Chemical Structure
  50. GC14794 PF-06463922

    Lorlatinib

    PF-06463922 (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor. PF-06463922 has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALKL1196M, respectively. PF-06463922 has anticancer activity. PF-06463922  Chemical Structure
  51. GC19362 Repotrectinib TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively. Repotrectinib  Chemical Structure
  52. GC48070 SB-431542 (hydrate) Inhibitor of receptors ALK4, ALK5, and ALK7 SB-431542 (hydrate)  Chemical Structure
  53. GC14349 SB525334

    TGF-β RI Kinase Inhibitor VIII

    (TGF-beta1) receptor inhibitor SB525334  Chemical Structure
  54. GC73129 SIAIS164018 hydrochloride SIAIS164018 drochloride is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 hydrochloride  Chemical Structure
  55. GC44903 SMAD3 Inhibitor, SIS3 SMAD3 Inhibitor, SIS3 is a potent and selective inhibitor of Smad3 phosphorylation. SMAD3 Inhibitor, SIS3  Chemical Structure
  56. GC16694 TAE684 (NVP-TAE684)

    TAE 684

    A selective ALK inhibitor TAE684 (NVP-TAE684)  Chemical Structure
  57. GC50562 TL 13-110 Negative control for TL 13-112 TL 13-110  Chemical Structure
  58. GC50563 TL 13-22 Negative control for TL 13-12 TL 13-22  Chemical Structure
  59. GC62260 TPX-0131

    TPX-0131

    TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). TPX-0131 has strong antitumor activities. TPX-0131  Chemical Structure
  60. GC62516 UNC5293 UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research. UNC5293  Chemical Structure
  61. GC19140 X-376 X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively. X-376  Chemical Structure
  62. GC62146 XST-14 XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects. XST-14  Chemical Structure
  63. GC64013 ZX-29 ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect. ZX-29  Chemical Structure

62 Item(s)

per page

Set Descending Direction